article thumbnail

Non-vaccine nasal spray could protect against COVID-19

pharmaphorum

That could be important if it takes longer than expected to bring vaccines and antibodies to market, said a spokesman for the companies, pointing to the news this week that AstraZeneca has halted phase 3 trials of its COVID-19 vaccine candidate AZD1222 after a serious adverse reaction in one patient.

Vaccines 133
article thumbnail

FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel

pharmaphorum

The most common adverse reactions seen in a trial cohort of 38,000 patients were at injection sites (84.1%) followed by fatigue (62.9%) and headache (55.1%), and serious adverse reactions occurred in 0% to 4.6% of participants.

Vaccines 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Moderna’s Covid-19/influenza vaccine phase III data highlights potential of mRNA technology for infectious diseases: GlobalData

Express Pharma

The investigational combination mRNA vaccine generated statistically significant higher immune responses in relation to the licensed comparator vaccines used in the randomised, observer-blind, active control study among 8,000 adults aged 50 years and older.

Vaccines 104
article thumbnail

US FDA approves Apellis’ geographic atrophy therapy Syfovre

Pharmaceutical Technology

It provides comprehensive control of the complement cascade, which is part of the immune system of the body, by targeting C3. Vitreous floaters, ocular discomfort, conjunctival hemorrhage, and neovascular AMD were the most common adverse reactions observed in patients receiving Syfovre.

article thumbnail

It’s been a long time coming for long-term topical psoriasis treatments

pharmaphorum

Anyone who watches television has heard the list of potential adverse reactions, considering that commercials for psoriasis treatments are seemingly only outnumbered by goofy ads for auto insurance. For moderate to severe cases, systemic biologics work to suppress the immune system and bring relief to the skin and joints.

article thumbnail

BMS Sotyktu approves for the Treatment of Moderate-to-Severe Plaque Psoriasis

LifeProNow

Psoriasis is a widely prevalent, chronic, systemic immune-mediated disease that impacts approximately 14 million people in Europe. The results are particularly meaningful for dermatologists and patients who have been waiting for a more effective and convenient oral therapy to help manage this serious, chronic, immune-mediated disease.”

article thumbnail

Novavax’s updated Covid-19 vaccine receives FDA emergency use authorisation

Pharmaceutical Business Review

The CDC’s Advisory Committee on Immunization Practices unanimously recommended the use of the 2024-2025 COVID-19 vaccines for individuals as young as six months in June this year. Headaches, nausea, muscle pain, and fatigue, among others were the most common adverse reactions to Novavax’s NVX-CoV2373 vaccine in clinical trials.